Analysts ponder soaring Arca shares

What's up at Arca Biopharma? Analysts have been scratching their heads trying to figure out why, after the developer announced a new patent on Friday--hardly earthshattering news--its stock would go up more than 200 percent. TheStreet's Adam Feuerstein suggests it could be the result of momentum trading, with a higher price building steam. Ironically, he adds, Arca disclosed that it still hasn't reached agreement with the FDA on its special protocol assessment for the new Phase III the agency demanded on bucindolol. And that's the kind of news that normally wouldn't excite investors. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.